Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Black, S, Wilcock, G, Haworth, J, Hendrix, S, Zavitz, K, Christensen, D, Binger, M, Bass, S, Laughlin, M, Swabb, E
বিন্যাস: Conference item
প্রকাশিত: 2006